Implementation of the Flexible Assertive Community Treatment (FACT) Model in Norway: eHealth Assessment Study

publishedVersio

Experiences and Expectations of Information and Communication Technologies in Flexible Assertive Community Treatment Teams: Qualitative Study

publishedVersio

An optimization based on simulation approach to the patient admission scheduling problem: Diagnostic imaging department case study

The growing influx of patients in healthcare providers is the result of an aging population and emerging self-consciousness about health. In order to guarantee the welfare of all the healthcare stakeholders, it is mandatory to implement methodologies that optimize the healthcare providers' efficiency while increasing patient throughput and reducing patient's total waiting time. This paper presents a case study of a conventional radiology workflow analysis in a Portuguese healthcare provider. Modeling tools were applied to define the existing workflow. Re-engineered workflows were analyzed using the developed simulation tool. The integration of modeling and simulation tools allowed the identification of system bottlenecks. The new workflow of an imaging department entails a reduction of 41 % of the total completion time. © 2013 Society for Imaging Informatics in Medicine

The (non) space of the young man in health policies regarding drugs in Brazil: genealogical approaches

O estudo buscou problematizar as negociações e as condições de possibilidade para inclusão ou exclusão dos homens jovens no processo de formulação das políticas de saúde sobre drogas no Brasil. Inscrito no campo de estudos sobre gênero e propondo-se a discutir a relação entre masculinidades e uso de drogas, numa perspectiva interseccional, o marco referencial considera que: a maior vulnerabilidade de homens jovens a problemas no uso de drogas e as dificuldades de acesso e/ou vinculação aos serviços também precisam ser compreendidos a luz das leituras sobre gênero e saúde; e a forma como as discussões de gênero se fazem presentes nas políticas, seja nos documentos oficiais, seja na compreensão das pessoas ligadas à elaboração e/ou implementação destas, influencia, direta ou indiretamente, na forma como esses homens são reconhecidos, acessam e são acolhidos pelos serviços do Sistema Único de Saúde. A partir de três entrevistas episódicas e semiestruturadas com gestores que participaram da elaboração das políticas de saúde sobre drogas, nas esferas municipal, estadual e federal, e do estudo dos documentos citados durante as entrevistas, elaboramos um texto genealógico que procura recontar a história das políticas de drogas no Brasil, a partir dos acontecimentos destacados pelos interlocutores

Disruption of BASIGIN decreases lactic acid export and sensitizes non-small cell lung cancer to biguanides independently of the LKB1 status

Most cancers rely on aerobic glycolysis to generate energy and metabolic intermediates. To maintain a high glycolytic rate, cells must efficiently export lactic acid through the proton-coupled monocarboxylate transporters (MCT1/4). These transporters require a chaperone, CD147/BASIGIN (BSG) for trafficking to the plasma membrane and function. To validate the key role of these transporters in lung cancer, we first analysed the expression of MCT1/4 and BSG in 50 non-small lung cancer (NSCLC) cases. These proteins were specifically upregulated in tumour tissues. We then disrupted BSG in three NSCLC cell lines (A549, H1975 and H292) via ‘Zinc-Finger Nucleases’. The three homozygous BSG-/- cell lines displayed a low MCT activity (10- to 5-fold reduction, for MCT1 and MCT4, respectively) compared to wild-type cells. Consequently, the rate of glycolysis, compared to the wild-type counterpart, was reduced by 2.0- to 3.5-fold, whereas the rate of respiration was stimulated in BSG-/- cell lines. Both wild-type and BSG-null cells were extremely sensitive to the mitochondria inhibitor metformin/ phenformin in normoxia. However, only BSG-null cells, independently of their LKB1 status, remained sensitive to biguanides in hypoxia in vitro and tumour growth in nude mice. Our results demonstrate that inhibiting glycolysis by targeting lactic acid export sensitizes NSCLC to phenformin.The JP team was funded from Ligue Nationale Contre le Cancer (LNCC Equipe labellisee), Fondation ARC, INCa, ANR, the EU-FP7 "METOXIA", SERVIER-CNRS, and Centre Lacassagne. SG received a fellowship from Fundacao para a Ciencia e Tecnologia (SFRH/BD/33503/2010) and IM was supported by a fellowship from LNCC. We thank Dr Susan Critchlow (AstraZeneca) for providing the iMCT1/2, the cytometry core facility (CYTOMED) for FACS analysis, and Dr. Christiane Brahimi-Horn for editorial correction of the manuscript

Methodology for Health Care Process Modelling: Bringing the Health Care Complexity into Health IT System Development

Abstrac

Gut Microbiota Diversity and C-Reactive Protein Are Predictors of Disease Severity in COVID-19 Patients

Funding Information: We acknowledge support from the NOVA Medical School of Universidade NOVA de Lisboa, CINTESIS, and CHRC. Funding. This study was sponsored by the Funda??o para a Ci?ncia e a Tecnologia (FCT, project no. 268_596883842), BIOCODEX, and CINTESIS (reference UIDB/4255/2020). The funders had no role in study design, data collection, data analysis, data interpretation, or manuscript writing. Publisher Copyright: © Copyright © 2021 Moreira-Rosário, Marques, Pinheiro, Araújo, Ribeiro, Rocha, Mota, Pestana, Ribeiro, Pereira, de Sousa, Pereira-Leal, de Sousa, Morais, Teixeira, Rocha, Silvestre, Príncipe, Gatta, Amado, Santos, Maltez, Boquinhas, de Sousa, Germano, Sarmento, Granja, Póvoa, Faria and Calhau.The risk factors for coronavirus disease 2019 (COVID-19) severity are still poorly understood. Considering the pivotal role of the gut microbiota on host immune and inflammatory functions, we investigated the association between changes in the gut microbiota composition and the clinical severity of COVID-19. We conducted a multicenter cross-sectional study prospectively enrolling 115 COVID-19 patients categorized according to: (1) the WHO Clinical Progression Scale—mild, 19 (16.5%); moderate, 37 (32.2%); or severe, 59 (51.3%), and (2) the location of recovery from COVID-19—ambulatory, 14 (household isolation, 12.2%); hospitalized in ward, 40 (34.8%); or hospitalized in the intensive care unit, 61 (53.0%). Gut microbiota analysis was performed through 16S rRNA gene sequencing, and the data obtained were further related to the clinical parameters of COVID-19 patients. The risk factors for COVID-19 severity were identified by univariate and multivariable logistic regression models. In comparison to mild COVID-19 patients, the gut microbiota of moderate and severe patients have: (a) lower Firmicutes/Bacteroidetes ratio; (b) higher abundance of Proteobacteria; and (c) lower abundance of beneficial butyrate-producing bacteria such as the genera Roseburia and Lachnospira. Multivariable regression analysis showed that the Shannon diversity index [odds ratio (OR) = 2.85, 95% CI = 1.09–7.41, p = 0.032) and C-reactive protein (OR = 3.45, 95% CI = 1.33–8.91, p = 0.011) are risk factors for severe COVID-19 (a score of 6 or higher in the WHO Clinical Progression Scale). In conclusion, our results demonstrated that hospitalized patients with moderate and severe COVID-19 have microbial signatures of gut dysbiosis; for the first time, the gut microbiota diversity is pointed out as a prognostic biomarker of COVID-19 severity.publishersversionpublishe

Use of e-health in Norwegian FACT teams : A user perspective

publishedVersio

Sistema de informação para recomendação de soluções de envernizamento

Relatório de projecto Programa Operacional Ciência e Inovação 201